ClinicalTrials.gg
RecruitingNCT07535008Updated Oct 21, 2026

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

An interventional study of Dental Cleaning and Dental Plaque sampling in Chronic Graft Versus Host Disease, Acute Graft Versus Host Disease and Hematopoietic and Lymphatic System Neoplasm, sponsored by Fred Hutchinson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Fred Hutchinson Cancer Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 21, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Bronchiolitis Obliterans Syndrome by Fred Hutchinson Cancer Center — 3 open to participants now, 6 under way, none of them phase 3. Bronchiolitis Obliterans Syndrome · Fred Hutchinson Cancer Center.

Started
2026
the only one that year
No phase
Only one
of the 11
Registered
11th of 11
by date

Among the 11 studies in Bronchiolitis Obliterans Syndrome by Fred Hutchinson Cancer Center, this one is the only one that started in 2026, is the only one with no phase, and was the 11th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

3 of the 11 studies in Bronchiolitis Obliterans Syndrome by Fred Hutchinson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Bronchiolitis Obliterans Syndrome by Fred Hutchinson Cancer Center, or all of them as a file.
02

Study summary

This clinical trial evaluates the feasibility and effectiveness of a post-transplant dental cleaning for the prevention of chronic graft versus host disease (GVHD) in patients undergoing an allogeneic hematopoietic cell transplant (HCT). HCT is the only curative treatment for some types of blood cancer. Unfortunately, this approach can lead to the development of GVHD, which is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Some research has shown that the bacteria that is present in the dental plaque soon after transplant may affect the development of chronic GVHD. Dental cleanings prior to transplant are part of the normal standard of care for patients undergoing HCT. Adding an additional cleaning shortly after HCT may be effective for preventing the development of chronic GVHD.

Read the detailed description

OUTLINE:

Patients who have not undergone dental cleaning within 3 months preceding the baseline visit undergo dental cleaning at baseline (before the initiation of transplant conditioning) according to standard of care. All patients undergo simplified dental cleaning on day +28 following HCT.

After completion of study intervention, patients are followed up on days +84 and +180 and at 1 year.

03

Conditions studied

  • Chronic Graft Versus Host Disease
  • Acute Graft Versus Host Disease
  • Hematopoietic and Lymphatic System Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • T-replete hematopoietic cell transplantation for any indication. History of prior transplantation is allowed. Any conditioning regimen is allowed
  • One of the following HCT donor types:

    • 9/10 or 10/10 human leukocyte antigen (HLA)-matched unrelated donor
    • Cord blood
  • Willing to have an in-person 1-year long-term follow-up (LTFU) visit including an oral medicine at Fred Hutch (FH)
  • Ability to understand and sign a written document (or legal representative)

Exclusion criteria

Exclusion Criteria:

  • Edentulous state
  • Bone marrow as graft source
  • Use of post-transplantation cyclophosphamide (PTCy) or ruxolitinib as prophylaxis
  • Use of anti-thymocyte globulin (ATG) in conditioning
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Prevention (dental cleaning)

    Patients undergo simplified dental cleaning on day +28 following HCT.

    Procedure: Dental Cleaning · Procedure: Dental Plaque sampling

Interventions

  • ProcedureDental Cleaning

    Dental cleaning

  • ProcedureDental Plaque sampling

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Probability of moderate-to-severe chronic graft versus host disease

    Time frame: At 1-year post-transplant

Secondary outcomes

  1. Probability of grade III-IV acute graft versus host disease

    Time frame: At 6-months post-transplant

  2. Proportion of eligible patients approached who consent (feasibility)

    Time frame: Up to 2 years

  3. Proportion of enrolled patients who receive the intervention (feasibility)

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Apr 2028, 23 months after the start.

Of 110 non-industry interventional studies with no phase under Bronchiolitis Obliterans Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 23 months is close to that.

Counting every sponsor, half of 122 studies reached it within 22 months; a quarter within 11 and three quarters within 54.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → May 2026, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2026
First posted
Apr 16, 2026
StartActual
May 12, 2026was Jun 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2029
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 11, 2026→May 12, 2026
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Start date Jun 11, 2026→May 12, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07535008
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
May 12, 2026
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Oct 21, 2026

Study contacts

Armin Rashidi, MD, PhD
Contact
arashidi@fredhutch.org
206-667-2506
Armin Rashidi, MD, PhD
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion